JSPR biotech catalysts & pipeline

JASPER THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

KP-104 (Vensobafusp alfa) — Interim data

Q4 2026

We expect to report interim data from Stage 1 of the ongoing Phase 2 basket trial in the fourth quarter of 2026 and updated data in the second quarter of 2027, and we plan to report interim data from Stage 2 of the study in the second quarter of 2027.

Source filing

briquilimab — FDA meeting

Q1 2027

Following positive, long-term data in severe combined immunodeficiency ("SCID"), we are progressing our efforts towards a pre-Biologics License Application ("BLA") meeting with the FDA and expect to announce next steps in the first quarter of 2027.

Source filing

Briquilimab — Regulatory decision

Q1 '27

Q1 '27: Receive regulatory guidance

Source filing

KP-104 (Vensobafusp alfa) — FDA meeting

H1 2027

Based on previous positive data in treatment-naïve PNH, we are planning for an end-of-Phase 2 meeting with the FDA and plan to announce next steps in the first half of 2027.

Source filing

KP-701 — IND submission

Q1 2027

In the first quarter of 2027, we expect to file a clinical trial application ("CTA") or an investigational new drug application ("IND") for Phase 1 testing, and we plan to report first-in-human data in the third quarter of 2027.

Source filing

KP-104 (Vensobafusp alfa) — Full data

Q2 '27

Q2 '27: Updated data (Stage 1)

Source filing

KP-701 — Initial data

Q3 2027

In the first quarter of 2027, we expect to file a clinical trial application ("CTA") or an investigational new drug application ("IND") for Phase 1 testing, and we plan to report first-in-human data in the third quarter of 2027.

Source filing

Explore the free biotech catalyst calendar